Clinical Trial Update: Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma

View source ↗

Summary

A completed clinical trial evaluated pralatrexate for relapsed or refractory peripheral T-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Folotyn (pralatrexate)

Snippet

Sponsor: Samsung Medical Center | Conditions: Relapsed or Refractory Peripheral T-cell Lymphoma | Status: COMPLETED